5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine: α2-AR Agonist Evidence & Protocols

Executive Summary: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (B3465, APExBIO) is a selective α2-adrenergic receptor agonist with a molecular weight of 292.13 and DMSO solubility of ≥25.7 mg/mL (source: product_spec). It demonstrates >98% HPLC purity and is validated for reproducible use in immune rejection modulation and post-surgery osteosarcoma recurrence research (source: Pei et al., 2025). In vivo, it reduces tumor recurrence by activating CD8+ T cell pathways without direct cytotoxicity (source: Pei et al., 2025). Protocols recommend storage at -20°C and immediate use after solution preparation for maximal stability (source: product_spec).

Biological Rationale

Osteosarcoma (OS) is a highly aggressive bone tumor with recurrence risk post-surgical resection. Immune evasion and resistance to checkpoint blockade remain major therapeutic hurdles (source: Pei et al., 2025). Adrenergic receptor (AR) signaling, particularly via the α2 subtype, modulates neurotransmitter release, vascular tone, and immune responses. While β-adrenergic blockers have established anti-tumor roles, α2-AR agonists such as 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine offer a new avenue for immune rejection modulation in post-surgery osteosarcoma recurrence treatment research (source: Pei et al., 2025).

Mechanism of Action of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

B3465 selectively activates α2-adrenergic receptors (α2-AR), which are G protein-coupled receptors (GPCRs) expressed on neuronal and immune cells (source: product_spec). Upon agonist binding, α2-ARs inhibit adenylate cyclase, reducing cAMP and modulating downstream signaling. In immunocompetent mouse models, α2-AR activation by B3465 triggers CD8+ T cell and TCR pathway activation, promoting anti-tumor immune responses without direct cytotoxicity to osteosarcoma cells (source: Pei et al., 2025). Proteomic and bioinformatics analyses highlight ITGAL as a central mediator. The compound’s high selectivity underpins its utility in neuroscience receptor modulation and immune studies (source: evidence_and_applications).

Evidence & Benchmarks

• B3465 (UK14,304) loaded in PLGA-PEG-PLGA hydrogel reduces tumor recurrence and growth in post-surgical osteosarcoma mouse models (source: Pei et al., 2025).
• No significant direct cytotoxicity observed on K7M2, 143b, or Khos osteosarcoma cell lines in vitro (source: Pei et al., 2025).
• Proteomic profiling links α2-AR activation to CD8+ T cell and TCR signaling, with ITGAL as a key node (source: Pei et al., 2025).
• High-purity (98–99.88%) and DMSO solubility ≥25.7 mg/mL enable robust experimental reproducibility (source: product_spec).
• Stability requires storage at -20°C and prompt use after solution preparation; shipping on blue ice (source: product_spec).

This article extends earlier discussions such as Advancing Osteosarcoma Recurrence Research by providing protocol-verified, literature-backed benchmarks and clarifying the immune mechanisms observed in vivo.

Applications, Limits & Misconceptions

B3465 is primarily validated for use in basic and translational research involving α2-adrenergic receptor signaling pathway studies, immune rejection modulation, and post-surgery osteosarcoma recurrence treatment research (source: Pei et al., 2025). Its high selectivity and solubility profile make it suitable for advanced neuroscience receptor modulation workflows (source: evidence_and_applications). However, it is not approved for diagnostic or therapeutic use in humans and has not been validated for other disease contexts unless supported by further peer-reviewed studies.

Common Pitfalls or Misconceptions

• Misconception: B3465 is cytotoxic to osteosarcoma cells. Correction: No direct cytotoxic effects were observed in vitro (source: Pei et al., 2025).
• Pitfall: Assuming water or ethanol solubility. Correction: The compound is insoluble in water and ethanol; use DMSO for dissolution (source: product_spec).
• Misconception: Suitable for clinical use. Correction: For research use only; not for diagnostic, therapeutic, or medical applications (source: product_spec).
• Pitfall: Neglecting storage or solution stability. Correction: Store at -20°C and use promptly after solution preparation (source: product_spec).
• Misconception: Broad GPCR agonism. Correction: B3465 is selective for α2-AR; off-target effects are not supported by current data (source: product_spec).

For expanded protocols and troubleshooting, see Applied Strategies Using 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine in α2-Adrenergic Receptor Research, which this article updates by adding new in vivo immune mechanism evidence.

Workflow Integration & Parameters

Protocol Parameters

• Assay: DMSO solubility | ≥25.7 mg/mL | Solution preparation | Enables high-concentration stocks for cell-based and in vivo work | product_spec
• Assay: HPLC purity | 98–99.88% | Quality control | Ensures reproducibility and minimizes confounders | product_spec
• Assay: Storage temperature | -20°C | Long-term storage | Maintains chemical stability and potency | product_spec
• Assay: Cell viability (K7M2/143b/Khos) | No cytotoxicity at tested doses | In vitro validation | Confirms immune modulation is not due to direct cell killing | Pei et al., 2025
• Assay: Tumor recurrence (BALB/c mouse) | Significant reduction | In vivo efficacy | Demonstrates immune-mediated anti-tumor effect | Pei et al., 2025
• Assay: Shipping condition | Blue ice | Logistics | Preserves sample during transport | product_spec

For a deeper exploration of workflow design, troubleshooting, and advanced applications, see Applied Use of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, which focuses on performance parameters. This article expands on those findings by providing peer-reviewed in vivo efficacy data.

Conclusion & Outlook

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, supplied by APExBIO, is a validated, high-purity α2-adrenergic receptor agonist for research on immune rejection modulation and post-surgery osteosarcoma recurrence (source: product_spec). Its selectivity and robust solubility underpin reliable receptor signaling and immune pathway interrogation. Current evidence supports its use in preclinical models for dissecting α2-AR-mediated immune mechanisms. Future research will determine its broader applicability in other immune modulation contexts, but translation to clinical or diagnostic applications is not supported by present data.